Becotatug Vedotin
drugOn this page
Also known as Anti-egfr adc mrg003Becotatug vedotinaBecotatug vedotineMrg 003Mrg-003Mrg003
Summary
Becotatug Vedotin (CHEMBL6068210) is a phase-3 clinical-stage antibody drug conjugate; indicated across 5 conditions including head and neck squamous cell carcinoma and neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody drug conjugate
- Indications: 5 conditions
- Clinical trials: 34
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068210 |
| Name | Becotatug Vedotin |
| Type | Antibody drug conjugate |
| Max phase | 3 |
Also known as: Anti-egfr adc mrg003, Becotatug vedotin, Becotatug vedotina, Becotatug vedotine, Mrg 003, Mrg-003, Mrg003, BECOTATUG VEDOTIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| head and neck squamous cell carcinoma | 3 | MONDO:0010150 | EFO:0000181 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| nasopharyngeal neoplasm | 2 | MONDO:0005375 | EFO:0004252 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 34.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 24 |
| PHASE3 | 5 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06976190 | PHASE3 | RECRUITING | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
| NCT07459296 | PHASE3 | RECRUITING | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC |
| NCT07481799 | PHASE3 | RECRUITING | Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases |
| NCT07524413 | PHASE3 | NOT_YET_RECRUITING | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma |
| NCT07598318 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations |
| NCT05751512 | PHASE3 | UNKNOWN | A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN |
| NCT04868162 | PHASE2 | RECRUITING | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck |
| NCT05126719 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma |
| NCT06959108 | PHASE2 | RECRUITING | Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck |
| NCT07267338 | PHASE2 | NOT_YET_RECRUITING | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC |
| NCT07303283 | PHASE2 | NOT_YET_RECRUITING | Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma |
| NCT07331428 | PHASE2 | NOT_YET_RECRUITING | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC |
| NCT07381075 | PHASE2 | NOT_YET_RECRUITING | A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma |
| NCT07381699 | PHASE2 | NOT_YET_RECRUITING | MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial |
| NCT07394244 | PHASE2 | NOT_YET_RECRUITING | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma |
| NCT07464366 | PHASE2 | RECRUITING | The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study |
| NCT07490119 | PHASE2 | NOT_YET_RECRUITING | Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer |
| NCT07496190 | PHASE2 | RECRUITING | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy |
| NCT07518979 | PHASE2 | NOT_YET_RECRUITING | EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer |
| NCT07522879 | PHASE2 | RECRUITING | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma |
| NCT07531979 | PHASE2 | NOT_YET_RECRUITING | Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 |
| NCT07536789 | PHASE2 | RECRUITING | Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma |
| NCT07545083 | PHASE2 | NOT_YET_RECRUITING | Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) |
| NCT07555860 | PHASE2 | NOT_YET_RECRUITING | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
| NCT07579598 | PHASE2 | NOT_YET_RECRUITING | ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma |
| NCT07586124 | PHASE2 | NOT_YET_RECRUITING | Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma |
| NCT07589049 | PHASE2 | NOT_YET_RECRUITING | Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study |
| NCT04838548 | PHASE2 | UNKNOWN | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer |
| NCT04838964 | PHASE2 | UNKNOWN | A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
| NCT05188209 | PHASE2 | UNKNOWN | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. |
| NCT05688605 | PHASE1/PHASE2 | UNKNOWN | A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors |
| NCT07054307 | PHASE1 | RECRUITING | MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma |
| NCT07584499 | PHASE1 | RECRUITING | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors |
| NCT04868344 | PHASE1 | COMPLETED | A Study of MRG003 in Patients With Advanced Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: head and neck squamous cell carcinoma